AI Article Synopsis
- The study aimed to evaluate the effectiveness of clonazepam in treating burning mouth syndrome (BMS) compared to a placebo.
- Twenty patients with idiopathic BMS were randomly assigned to receive either clonazepam or a lactose placebo, with results showing significant pain relief in those taking clonazepam.
- Despite improvements in pain ratings, no significant changes were noted in mood or depression scores, suggesting that while clonazepam helps with pain, it may not impact emotional well-being.
Article Abstract
Objectives/hypothesis: In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results. The aim of the present randomized clinical trial was to determine the efficacy of clonazepam, a GABA agonist designed as an antiepileptic drug that exerts the typical effects of benzodiazepines.
Study Design: Randomized clinical trial.
Methods: Twenty patients with idiopathic BMS were carefully selected. Clonazepam (0.5 mg/day, n = 10) or placebo (lactose, n = 10) were randomly assigned to the patients.
Results: Patients on clonazepam significantly improved in pain ratings (P < .001). These changes were less pronounced in the placebo group (P < .11). No significant changes were observed in a mood scale (P = .56) or for depression scores (P = .56). Taste test and salivary flow increased over sessions, but were not different between groups (P = .83 and P = .06, respectively).
Conclusions: Clonazepam appears to have a positive effect on pain in BMS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/lary.22490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!